Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

The Lancet Oncology

Volumn 18, Issue 5, 2017, Pages 631-639

  Kudo, Toshihiro ^a   Hamamoto, Yasuo ^b   Kato, Ken ^c   Ura, Takashi ^d   Kojima, Takashi ^e   Tsushima, Takahiro ^f   Hironaka, Shuichi ^g   Hara, Hiroki ^h   Satoh, Taroh ^a   Iwasa, Satoru ^c   Muro, Kei ^d   Yasui, Hirofumi ^f   Minashi, Keiko ^g   Yamaguchi, Kensei ^h,i   Ohtsu, Atsushi ^e,j   Doki, Yuichiro ^a   Kitagawa, Yuko ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g CHIBA CANCER CENTER   (Japan)

^h Saitama Cancer Centre   (Japan)

ⁱ CANCER INSTITUTE HOSPITAL   (Japan)

^j National Cancer Center   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CREATINE KINASE; DIPHENHYDRAMINE; FLUOROPYRIMIDINE; GAMMA GLUTAMYLTRANSFERASE; NIVOLUMAB; PARACETAMOL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHOLESTASIS; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; LIVER FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OPEN STUDY; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; PRIMARY TUMOR; RASH; TREATMENT RESPONSE; AGED; ANOREXIA; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; LUNG DISEASE; MICROBIOLOGY; MIDDLE AGED; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANOREXIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DEHYDRATION; DYSPNEA; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPONATREMIA; LUNG DISEASES; MALE; MIDDLE AGED; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT;

EID: 85018782053     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30181-X     Document Type: Article

References (39)

1. 1 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Thrift, AP, The epidemic of oesophageal carcinoma: where are we now?. Cancer Epidemiol 41 (2016), 88–95.
3. 3 Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A, Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
4. 4 Tachimori, Y, Ozawa, S, Numasaki, H, et al. Comprehensive registry of esophageal cancer in Japan, 2009. Esophagus 13 (2016), 110–137.
5. 5 Ishiguro, S, Sasazuki, S, Inoue, M, et al. Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study). Cancer Lett 275 (2009), 240–246.
6. 6 Sakata, K, Hoshiyama, Y, Morioka, S, et al. Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. J Epidemiol 15:suppl 2 (2005), S212–S219.
7. 7 Secretan, B, Straif, K, Baan, R, et al. A review of human carcinogens—part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 10 (2009), 1033–1034.
8. 8 Steevens, J, Schouten, LJ, Goldbohm, RA, van den Brandt, PA, Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut 59 (2010), 39–48.
9. 9 National Cancer Center. Monitoring of cancer incidence in Japan MCIJ2012. http://ganjoho.jp/data/reg_stat/statistics/brochure/mcij2012_report.pdf, March, 2016 (accessed Dec 28, 2016).
10. 10 NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): esophageal and esophogastric junction cancers. Version 2.2016, 2016, National Comprehensive Cancer Network, Fort Washington, PA.
11. 11 NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): gastric cancer. Version 3.2016, 2016, National Comprehensive Cancer Network, Fort Washington, PA.
12. 12 Kuwano, H, Nishimura, Y, Oyama, T, et al. Guidelines for diagnosis and treatment of carcinoma of the eophagus April 2012 edited by the Japan Esophageal Society. Esophagus 12 (2015), 1–30.
13. 13 Raufi, AG, Klempner, SJ, Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol 6 (2015), 561–569.
14. 14 Sharpe, AH, Wherry, EJ, Ahmed, R, Freeman, GJ, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8 (2007), 239–245.
15. 15 Okazaki, T, Honjo, T, PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19 (2007), 813–824.
16. 16 Nurieva, RI, Liu, X, Dong, C, Yin-yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 229 (2009), 88–100.
17. 17 Ohigashi, Y, Sho, M, Yamada, Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11 (2005), 2947–2953.
18. 18 Sharma, P, Allison, JP, The future of immune checkpoint therapy. Science 348 (2015), 56–61.
19. 19 Qiu, H, Zheng, L, Tang, W, Yin, P, Cheng, F, Wang, L, Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. Clin Biochem 47 (2014), 612–617.
20. 20 Brahmer, JR, Drake, CG, Wollner, I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 (2010), 3167–3175.
21. 21 Hamanishi, J, Mandai, M, Ikeda, T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33 (2015), 4015–4022.
22. 22 Bristol-Myers Squibb. Annex I, summary of product characteristics: nivolumab BMS 10 mg/mL concentrate for solution for infusion. http://ec.europa.eu/health/documents/community-register/2015/20150720132394/anx_132394_en.pdf, 2015 (accessed Jan 5, 2017).
23. 23 Bristol-Myers Squibb. Highlights of prescribing information: Opdivo (nivolumab), for intravenous use. https://packageinserts.bms.com/pi/pi_opdivo.pdf (accessed Jan 5, 2017).
24. 24 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
25. 25 Gisele, C, Ian, FT, Placebo effects in oncology. J Natl Cancer Inst 95 (2003), 19–29.
26. 26 Muro, K, Hamaguchi, T, Ohtsu, A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15 (2004), 955–959.
27. 27 Kato, K, Tahara, M, Hironaka, S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67 (2011), 1265–1272.
28. 28 Ferris, RL, Blumenschein, G Jr, Fayette, J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
29. 29 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
30. 30 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
31. 31 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
32. 32 Fukushima, R, Iwasa, S, Shoji, H, et al. A retrospective analysis of irinotecan for heavily pretreated esophageal squamous cell carcinoma. Ann Oncol, 2014 pubished online Oct 1. https://doi.org/10.1093/annonc/mdu435.83.
33. 33 Dutton, SJ, Ferry, DR, Blazeby, JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 15 (2014), 894–904.
34. 34 Crosby, T, Hurt, CN, Falk, S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14 (2013), 627–637.
35. 35 Nishino, M, Jagannathan, JP, Krajewski, KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198 (2012), 737–745.
36. 36 Hodi, FS, Hwu, WJ, Kefford, R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34 (2016), 1510–1517.
37. 37 Abdel-Wahab, N, Shah, M, Suarez-Almazor, ME, Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One, 11, 2016, e0160221.
38. 38 Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
39. 39 Gettinger, S, Rizvi, NA, Chow, LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 34 (2016), 2980–2987.